Traceless, aptamer-based cell isolation for cell therapy applications

用于细胞治疗应用的无痕、基于适体的细胞分离

• 批准号: 10633756
• 负责人: Suzie H. Pun
• 金额: $ 34.25万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10633756
• 关键词: Adoption; Antibodies; Autologous; Binding; Biological; Biomanufacturing; CAR T cell therapy; CD34 gene; CD4 Positive T Lymphocytes; CD8-Positive T-Lymphocytes; CD8B1 gene; Cell Separation; Cell Survival; Cell Therapy; Cells; Cellular immunotherapy; Clinic; Clinical; Clinical Treatment; Clinical Trials; Collection; Complex; DNA; Data; Dendritic Cells; Development; Diabetes Mellitus; Disease; Engineering; Ensure; Ethics; Gene Expression Profiling; Generations; Goals; Harvest; Heart Diseases; Hematologic Neoplasms; Human; Immune Targeting; Immunotherapy; Logistics; Macrophage; Magnetism; Membrane Proteins; Methods; Outcome; Pharmaceutical Preparations; Phenotype; Population; Production; Recombinants; Regenerative Medicine; Reporting; Reproducibility; Research; SELL gene; Sampling; Source; Speed; Spinal cord injury; T memory cell; T-Lymphocyte; T-Lymphocyte Subsets; TNFRSF6 gene; Technology; Therapeutic; Time; Translations; Urine; aptamer; cell transformation; chimeric antigen receptor T cells; cost; gene product; glycosylation; improved; innovation; manufacture; monocyte; next generation; novel; peripheral blood; proteoliposomes; receptor; regenerative; response; small molecule; stem cell therapy; stem cells; success; technology platform

PROJECT SUMMARY Cell therapies are living drugs that can access a multifaceted biological response and can therefore potentially provide not only therapeutic but also regenerative outcomes. However, these beneficial attributes of cell therapeutics are accompanied by significantly more complex, variable, and costly production logistics. Major advances in biomanufacturing are required for cell therapies to have broad and widespread use. In this application, we propose to develop aptamer-based technologies for cell separation that will provide an impactful improvement over current technology, resulting in superior product at a fraction of the cost. Our main objectives are to 1) establish a novel SELEX method for membrane proteins and identify new aptamers for cell isolation applications, 2) develop methods for traceless isolation of monocytes and generation of macrophage and dendritic cell products for immunotherapy, 3) demonstrate multiplexed selection and T cell subset selection for CAR T cell immunotherapy applications, and 4) enable efficient collection and expansion of urine stem cells as a source for regenerative medicine therapies. Successful completion of these aims will lead to a platform technology for scalable and more affordable production of CAR T cell immunotherapy, monocyte-based cell therapies and stem cell treatments.

项目总结 细胞疗法是活的药物，可以获得多方面的生物反应，并可以 因此，不仅有可能提供治疗效果，而且有可能产生再生效果。然而，这些 细胞疗法的有益属性伴随着更加复杂、多变、 和昂贵的生产物流。细胞疗法需要生物制造方面的重大进展 具有广泛而广泛的用途在这个应用中，我们建议开发基于适体的 细胞分离技术将比目前的技术有更大的改进 技术，以极低的成本生产出卓越的产品。我们的主要目标是1) 膜蛋白SELEX方法的建立及新的细胞适配子的鉴定 分离应用，2)开发无痕迹分离单核细胞的方法和产生 巨噬细胞和树突状细胞产品用于免疫治疗，3)展示多重选择 和T细胞亚群选择，用于CAR T细胞免疫治疗应用，以及4)实现高效 收集和扩增尿液干细胞，作为再生医学疗法的来源。 这些目标的成功实现将带来可扩展和更多的平台技术 负担得起的CAR T细胞免疫疗法、基于单核细胞的细胞疗法和干细胞的生产 治疗。